Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis

被引：5
作者：
Budakoglu, B [1 ]
Abali, H [1 ]
Uncu, D [1 ]
Yildirim, N [1 ]
Öksüzoglu, B [1 ]
Zengin, N [1 ]
机构：
[1] SB Ankara Numune Hastanesi, Tibbi Onkol Klin, Ankara, Turkey
来源：
JOURNAL OF CHEMOTHERAPY | 2005年 / 17卷 / 04期
关键词：
colorectal cancer; hemodialysis; irinotecan;
D O I：
10.1179/joc.2005.17.4.452
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pharmacokinetic properties of many antineoplastic agents or their metabolites change with organ dysfunction. Unfortunately, chemotherapy doses determined in phase I and II studies in patients with normal hepatic and renal reserves are not usually applicable to those with hepatic and/or renal dysfunction. Considering the high incidence of colorectal adenocarcinoma, it is not unusual for a colorectal cancer patient to be on chronic hemodialysis. We report a patient with metastatic colorectal cancer on chronic hemodialysis who tolerated weekly irinotecan at 50 mg/m(2) well without significant toxicity. We briefly discuss therapeutic dose modification in such patients.
引用
收藏
页码：452 / 453
页数：2
相关论文
共 10 条
  • [1] [Anonymous], 2005, PRINCIPLES PRACTICE
  • [2] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    Cunningham, D
    Pyrhönen, S
    James, RD
    Punt, CJA
    Hickish, TF
    Heikkila, R
    Johannesen, TB
    Starkhammar, H
    Topham, CA
    Awad, L
    Jacques, C
    Herait, P
    [J]. LANCET, 1998, 352 (9138) : 1413 - 1418
  • [3] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    Douillard, JY
    Cunningham, D
    Roth, AD
    Navarro, M
    James, RD
    Karasek, P
    Jandik, P
    Iveson, T
    Carmichael, J
    Alakl, M
    Gruia, G
    Awad, L
    Rougier, P
    [J]. LANCET, 2000, 355 (9209) : 1041 - 1047
  • [4] Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy:: Efficacy and prognostic factors
    Karaoglu, A
    Yalcin, S
    Tekuzman, G
    Kars, A
    Çelik, I
    Güler, N
    Özisik, Y
    Türker, A
    Barista, I
    Güllü, I
    [J]. TUMORI, 2003, 89 (02) : 141 - 145
  • [5] PITOT HC, 1997, J CLIN ONCOL, V15, P251
  • [6] Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel
    Rothenberg, ML
    Meropol, NJ
    Poplin, EA
    Van Cutsem, E
    Wadler, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 3801 - 3807
  • [7] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    Saltz, LB
    Cox, JV
    Blanke, C
    Rosen, LS
    Fehrenbacher, L
    Moore, MJ
    Maroun, JA
    Ackland, SP
    Locker, PK
    Pirotta, N
    Elfring, GL
    Miller, LL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) : 905 - 914
  • [8] PHASE-II STUDY OF CPT-11, A NEW CAMPTOTHECIN DERIVATIVE, IN METASTATIC COLORECTAL-CANCER
    SHIMADA, Y
    YOSHINO, M
    WAKUI, A
    NAKAO, I
    FUTATSUKI, K
    SAKATA, Y
    KAMBE, M
    TAGUCHI, T
    OGAWA, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) : 909 - 913
  • [9] Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure
    Stemmler, J
    Weise, A
    Hacker, U
    Heinemann, V
    Schalhorn, A
    [J]. ONKOLOGIE, 2002, 25 (01): : 60 - 63
  • [10] A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
    Venook, AP
    Klein, CE
    Fleming, G
    Hollis, D
    Leichman, CG
    Hohl, R
    Byrd, J
    Budman, D
    Villalona, M
    Marshall, J
    Rosner, GL
    Ramirez, J
    Kastrissios, H
    Ratain, MJ
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (12) : 1783 - 1790
1